Intuitive Surgical (ISRG)
(Delayed Data from NSDQ)
$507.42 USD
+1.08 (0.21%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $507.62 +0.20 (0.04%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$507.42 USD
+1.08 (0.21%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $507.62 +0.20 (0.04%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth B Momentum C VGM
Zacks News
3 Medical Instruments Industry Stocks to Buy on genAI and M&A Boost
by Urmimala Biswas
ISRG, MASI and VCYT from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and wage and supply issues mar the prospects.
3 Red Hot Stocks Flashing Buy Signals: DVA, ISRG, SN
by Derek Lewis
Stocks making new highs tend to make even higher highs, particularly when positive earnings estimate revisions hit the tape. And that's precisely what these three companies have seen.
CVS Stock Gains From Its Birth Control Prescribing Service Launch
by Zacks Equity Research
CVS Health announces that nearly 400 CVS Pharmacy locations in Massachusetts have started offering hormonal contraceptive prescribing services.
Reasons to Retain Inari Medical Stock in Your Portfolio for Now
by Zacks Equity Research
NARI continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.
Roche Stock to Benefit From Accu-Chek Smartguide Launch in Europe
by Zacks Equity Research
RHHBY's Accu-Chek Smartguide will provide several predictive features aimed at enhancing patient safety. However, the device may face tough competition from existing CGM devices.
Labcorp Stock Gains From Market Expansion Efforts Amid Macro Woes
by Zacks Equity Research
LH is well-placed for long-term success in Cell & Gene Therapy, expanding into the consumer market and international growth through the specialty testing and biopharma business.
Sanara Stock Gains From New US Distribution Deal With ChemoMouthPiece
by Zacks Equity Research
SMTI, along with InfuSystem, inked a U.S. distribution agreement with ChemoMouthpiece. Under the agreement, ChemoMouthpiece's oral cryotherapy device will be distributed in cancer centers.
Intuitive Surgical, Inc. (ISRG) Rises Higher Than Market: Key Facts
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) concluded the recent trading session at $490.93, signifying a +1.38% move from its prior day's close.
Intuitive Surgical, Inc. (ISRG) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Intuitive Surgical (ISRG) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
The Zacks Rank Explained: How to Find Strong Buy Medical Stocks
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.
Paragon 28 Stock Gains From the Latest Launch of Its Right-Angle Drill
by Zacks Equity Research
FNA launched the Right-Angle Drill to enhance the APEX 3D Total Ankle Replacement System. The drill is designed to improve tibia preparation.
Reasons to Retain ResMed Stock in Your Portfolio for Now
by Zacks Equity Research
Strong demand for RMD's market-leading mask portfolio raises investors' optimism.
The Zacks Analyst Blog Highlights Prosus, Intuitive Surgical and Unilever
by Zacks Equity Research
Prosus, Intuitive Surgical and Unilever are included in this Analyst Blog.
August U.S. CPI Data: Global Week Ahead
by John Blank
Investors are on edge -- ahead of more key macro events -- that could shape the tone for trading in the weeks ahead.
Will Trinity Biotech Stock Gain From Its Latest Patent Process?
by Zacks Equity Research
TRIB announces updates on its European patented process. The company aims to use this process to improve the functionality of its glucose biosensor in its next-gen CGM technology.
5 Top Red-Hot Stocks to Buy Now
by Tracey Ryniec
he hottest stocks might not be those you think. Look past AI and technology stocks.
Here's Why Universal Health Shares are Attracting Investors Now
by Zacks Equity Research
UHS remains well-poised for growth on improved patient days at its behavioral healthcare facilities, acquisitions and solid cash flows.
PBH Stock Might Get a Boost From Focused Brand-Building Efforts
by Zacks Equity Research
Prestige Consumer puts emphasis on brand building and product innovation in niche consumer healthcare categories to improve the lives of its consumers.
Will Paragon 28 Stock Gain From the Latest Product Launch of R3FLEX?
by Zacks Equity Research
FNA recently introduced the R3FLEX Stabilization System, whose design should allow surgeons to restore a patient's soft tissue to a more natural anatomy.
Align Technology Stock Dips on Macroeconomic Issues, FX Headwind
by Zacks Equity Research
ALGN is facing a decline in Invisalign ASPs for comprehensive treatment options. This is resulting in a decline in the company's revenues.
Abbott's Lingo CGM System Gains U.S. Availability: Stock to Gain?
by Zacks Equity Research
ABT made its CGM system Lingo available in the United States. The system can be used by consumers aged 18 years and older who are not on insulin.
Intuitive Surgical, Inc. (ISRG) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
In the most recent trading session, Intuitive Surgical, Inc. (ISRG) closed at $476.69, indicating a -1.05% shift from the previous trading day.
Intuitive Surgical Gains 40.5% Year to Date: What's Driving the Stock?
by Zacks Equity Research
ISRG's shares gain on the back of strength in da Vinci surgical system.
QIAGEN Stock Likely to Gain on Collaboration for APOE Genotyping
by Zacks Equity Research
QGEN collaborates with Eli Lilly to develop a QIAstat-Dx IVD panel for APOE genotyping.
Intuitive Surgical, Inc. (ISRG) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
The latest trading day saw Intuitive Surgical, Inc. (ISRG) settling at $481.73, representing a -0.35% change from its previous close.